Sun Pharmaceutical Industries has reported results for fourth quarter and year ended March 31, 2019.
The company has reported a 2-fold jump in its net profit at Rs 1068.06 crore for the quarter under review as compared to Rs 504.62 crore for the same quarter in the previous year. Total income of the company increased by 13.07% at Rs 3,231.36 crore for Q4FY19 as compared Rs 2,857.77 crore for the corresponding quarter previous year.
On the consolidated basis, the company has reported a fall of 54.41% in its net profit at Rs 723.05 crore for the quarter under review as compared to Rs 1,585.85 crore for the same quarter in the previous year. However, total income of the company marginally increased by 2.27% at Rs 7,445.45 crore for Q4FY19 as compared Rs 7,279.85 crore for the corresponding quarter previous year.
For the year ended March 31, 2019, the company has reported around 3-fold jump in its net profit at Rs 816.60 crore as compared to Rs 305.64 crore for the previous year. Total income of the company increased by 14.21% at Rs 11,574.65 crore for year under review as compared to Rs 10,134.29 crore for year ended March 31, 2018.
For the year ended March 31, 2019, on the consolidated basis, the company has reported a rise of 24.98% in its net profit at Rs 3,209.32 crore as compared to Rs 2,567.94 crore for the previous year. Total income of the company increased by 10.11% at Rs 30,091.40 crore for year under review as compared to Rs 27,328.22 crore for year ended March 31, 2018.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: